GLIA: A novel drug discovery target for clinical pain
Top Cited Papers
- 1 December 2003
- journal article
- review article
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 2 (12), 973-985
- https://doi.org/10.1038/nrd1251
Abstract
No abstract availableKeywords
This publication has 111 references indexed in Scilit:
- Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's diseaseGut, 2002
- Complete Resolution of Reflex Sympathetic Dystrophy With Thalidomide TreatmentArchives of Internal Medicine, 2001
- lnterleukin-10 in the BrainCritical Reviews in Immunology, 2001
- Neuronal Plasticity: Increasing the Gain in PainScience, 2000
- ANTICYTOKINE THERAPIES FOR ACUTE INFLAMMATION AND THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME: IL-10 AND ISCHEMIA/REPERFUSION INJURY AS A NEW PARADIGMShock, 2000
- Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritisArthritis & Rheumatism, 2000
- Dynamic regulation of the proinflammatory cytokine, interleukin-1β: Molecular biology for non-molecular biologistsLife Sciences, 1999
- Thalidomide Inhibits Tumor Necrosis Factor- Production by Lipopolysaccharide- and Lipoarabinomannan-Stimulated Human Microglial CellsThe Journal of Infectious Diseases, 1995
- Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.The Journal of Experimental Medicine, 1993
- Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injuryBrain Research, 1991